Clinical Trial Update: 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial

View source ↗

Summary

The expanded access trial of the radiopharmaceutical 68Ga-DOTATOC for imaging neuroendocrine tumors is no longer available.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumor

Drugs mentioned

• 68Ga-DOTATOC (DOTATOC)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Neuroendocrine Tumors | Status: NO_LONGER_AVAILABLE